ArticleMikrochimica acta2025
Enhanced Alzheimer's biomarker detection using a ternary composite electrochemical aptasensor.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanomaterial strategies for mitigating protein misfolding and neuroinflammation in neurodegenerative diseases.Zoological research · 2026Review
- Carbon Nanomaterial-Based Electrochemical Biosensors for Alzheimer's Disease Biomarkers: Progress, Challenges, and Future Perspectives.Biosensors · 2025Review
- Biological applications of graphene-based nanomaterials in neurodegenerative diseases.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of a highly sensitive electrochemical aptasensor is reported that combines the unique properties of graphene, metallic oxides, and conducting polymers to overcome the limitations of sensitivity and specificity required for early diagnosis of Alzheimer's desease (AD). The sensor design utilizes a ternary composite of polypyrrole (PPy), reduced graphene oxide (rGO), and Fe₂O₃ nanoparticles, which synergistically enhance signal amplification, conductivity, and biocompatibility. The aptasensor leverages aptamers as biorecognition elements for the specific detection of Aβ1-40 oligomers. Electrochemical techniques, including cyclic voltammetry (CV), differential pulse voltammetry (DPV), and electrochemical impedance spectroscopy (EIS), were employed to characterize and evaluate the sensor's performance. The fabricated aptasensor demonstrated an extraordinary detection limit of 40 fM and a broad linear detection range from 0.1 pM to 200 nM, with exceptional sensitivity and selectivity. Furthermore, the sensor exhibited excellent reproducibility and stability, essential for real-world clinical applications. Real-sample testing using artificial serum further validated the aptasensor's reliability, showcasing its potential for early diagnosis and monitoring of AD. The robust platform and modular design of the sensor also pave the way for its adaptation to detect other target biomolecules by simply modifying the aptamer. This work represents a significant advancement in biosensor technology, offering a versatile, highly sensitive tool for biomedical diagnostics and personalized medicine.
Indexed as
Identifiers
39955684What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.